Table 1.
Effects of the three groups on the proportion of T lymphocytes
| Surface marker | PBS + control (%) | mIFN-α + control (%) | mIFN-α + YB-1siRNA (%) |
|---|---|---|---|
| NK1.1+ CD3− (lymphocyte-gated) | 5.3 ± 0.21* | 5.5 ± 0.54 | 5.1 ± 0.49 |
| CD4+ CD8− (CD3+-gated) | 47.6 ± 3.5* | 46.7 ± 5.1 | 47.3 ± 5.0 |
| CD4− CD8+ (CD3+-gated) | 27.6 ± 3.5* | 28.6 ± 3.0 | 28.3 ± 3.1 |
| CD44+ CD8+ (lymphocyte-gated) | 8.3 ± 2.5* | 9.3 ± 1.5 | 8.3 ± 3.5 |
| CD25+ foxp3+ (CD4+-gated) | 11.8 ± 1.7* | 11.0 ± 1.3 | 12.6 ± 1.9 |
NK1.1+ CD3−, CD4+ CD8−, CD4− CD8+, CD44+ CD8+, and CD25+ foxp3+ cells demonstrate NK cells, CD4 T cells, CD8 T cells, memory CD8 T cells, and regulatory T cells, respectively
Abs and reagents: Fluorescein isothiocyanate (FITC)-conjugated anti-CD44 (IM7), anti-Foxp3 (FJK-16s), anti-CD3 (145-2C11), and anti-CD25 mAbs (7D4); phycoerythrin (PE)-conjugated anti-NK1.1 (DX-5) and anti-CD8 mAbs (53–6.7); allophycocyanin (APC)-conjugated anti-CD3, anti-Foxp3, and anti-CD44 mAbs were purchased from e-Bioscience (San Diego, CA). PerCP-Cy5.5-labeled anti-CD4 mAb was purchased from BD PharMingen (San Diego, CA). Armenian Hamster IgG1 was purchased from Wako Pure Chemicals (Osaka, Japan)
* Not specific compared with the other 2 groups